01 22Gowling WLG (Canada) LLP
Patent Expiration Date : 1931-11-17
Date Granted : 2018-06-12
Brand Name : HEMLIBRA
Patent Number : 2817964
Filing Date : 2011-11-17
Strength per Unit : 12 mg / 0.4 mL
Dosage Form : SOLUTION
Human Or VET : Human
Route of Administration : SUBCUTANEOUS
Patent Expiration Date : 1931-11-17
Date Granted : 2018-06-12
Patent Expiration Date : 1931-11-17
Date Granted : 2018-06-12
Brand Name : HEMLIBRA
Patent Number : 2817964
Filing Date : 2011-11-17
Strength per Unit : 300 mg / 2 mL
Dosage Form : SOLUTION
Human Or VET : Human
Route of Administration : SUBCUTANEOUS
Patent Expiration Date : 1931-11-17
Date Granted : 2018-06-12
Patent Expiration Date : 2026-03-31
Date Granted : 2017-03-21
Brand Name : HEMLIBRA
Patent Number : 2603264
Filing Date : 2006-03-31
Strength per Unit : 12 mg / 0.4 mL
Dosage Form : SOLUTION
Human Or VET : Human
Route of Administration : SUBCUTANEOUS
Patent Expiration Date : 2026-03-31
Date Granted : 2017-03-21
Patent Expiration Date : 2026-03-31
Date Granted : 2017-03-21
Brand Name : HEMLIBRA
Patent Number : 2603264
Filing Date : 2006-03-31
Strength per Unit : 300 mg / 2 mL
Dosage Form : SOLUTION
Human Or VET : Human
Route of Administration : SUBCUTANEOUS
Patent Expiration Date : 2026-03-31
Date Granted : 2017-03-21
Patent Expiration Date : 1930-12-24
Date Granted : 2019-01-22
Brand Name : HEMLIBRA
Patent Number : 2785414
Filing Date : 2010-12-24
Strength per Unit : 12 mg / 0.4 mL
Dosage Form : SOLUTION
Human Or VET : Human
Route of Administration : SUBCUTANEOUS
Patent Expiration Date : 1930-12-24
Date Granted : 2019-01-22
Patent Expiration Date : 1930-12-24
Date Granted : 2019-01-22
Brand Name : HEMLIBRA
Patent Number : 2785414
Filing Date : 2010-12-24
Strength per Unit : 300 mg / 2 mL
Dosage Form : SOLUTION
Human Or VET : Human
Route of Administration : SUBCUTANEOUS
Patent Expiration Date : 1930-12-24
Date Granted : 2019-01-22
